Last week, the European Specialist Nurses Organisations (ESNO) released a document aimed at assisting nurses in the management of switching a patient from a reference biologic to a biosimilar.
Last week, the European Specialist Nurses Organisations (ESNO) released a document aimed at assisting nurses in the management of switching a patient from a reference biologic to a biosimilar. The guidelines specifically address the role of specialized nurse interactions with patients during the switching process and build upon existing European Commission guidelines for the healthcare community.
“Switching between similar biological medicines needs good management. Nurses play a crucial role in communicating with patients and providing support and reassurance, before, during, and after the switch,” said Ber Oomen, executive director at ESNO, in a statement.
Nurses have firsthand experience in leading the transition between a reference biologic and a biosimilar. In order to address the important interactions nurses have with patients, the guidelines include points around how to better inform and clearly communicate information about biologics and biosimilars.
Specifically, the guidelines contain talking points around the benefits of biosimilars such as increasing patient access to drugs, how to address patient questions or concerns if they are hesitant about switching, and exercising proper pharmacovigilance.
In addition, there are multiple case studies and real-world data included in the document that reinforce biosimilars' safe and effective use. “The quality, safety, and efficacy of biosimilar medicines are assessed and tested with comparability studies (including clinical trials) before the medicine is approved,” read the guidelines.
The guide was created by the ESNO community “based on similar initiatives across Eruope where switching programs are already in place.” For convenience, the authors also created a pocket dictionary for nurses that includes frequently asked questions from patients and how to address them.
“This is built on nurses’ many years of education, and their experience with patients in different therapies. It is a process that requires time, patience, and care… Patients need to know that their healthcare professionals understand the reasoning behind the switch and are confident that it is the right thing to do. This guide aims to achieve that,” said Oomen.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.